In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1855 News Items found
Joyce Tyson
In the Clinic
International Study Shows Liquid Biopsies May Improve Lung Cancer Survival

An international study led by MSK investigators has found that liquid biopsies may improve survival in people with lung cancer. These blood tests are easier for patients than more traditional tissue biopsies.
Postdocs Francisco “Pancho” Barriga and Kaloyan Tsanov in the lab
New MACHETE Technique Slices Into Cancer Genome To Study Copy Number Alterations

Learn why MSK researchers developed MACHETE, a new CRISPR-based technique to study large-scale genetic deletions efficiently in laboratory models.
MSK thoracic surgeon and lung cancer specialist David Jones.
Inherited BRMS1 Mutation Promotes Lung Cancer Spread, MSK Research Suggests

An inherited mutation that contributes to lung cancer spread could be a target for therapies.
Selwyn M. Vickers, M.D., FACS
Selwyn M. Vickers Named to amNY Metro and PoliticsNY’s Power Players in Healthcare List

The list acknowledges and celebrates healthcare leaders who envision a better future for all New Yorkers and constitute New York’s ever-expanding and constantly improving healthcare system.
MSK medical oncologist and genitourinary cancer specialist Emily Feld
Feature
Interpreting Bladder Cancer Symptoms in Men vs. Women: What You Should Know

Learn what bladder cancer symptoms can mean in men and women.
Nancy Schroeder and her husband Mark
In the Clinic
New Checkpoint Inhibitor Immunotherapy Treatment for Advanced Melanoma Shows Promise

Results from a phase 2 clinical trial report a combination of two checkpoint inhibitor immunotherapy drugs given before melanoma surgery prevents this aggressive skin cancer from coming back. This new drug combination also has fewer side effects than other immunotherapy treatments.
MSK hematologic oncologist Saad Usmani, who specializes in treating multiple myeloma.
FDA Approves Teclistamab, a Promising New Drug for Multiple Myeloma Targeting BCMA and CD3 Proteins

Learn how FDA approval of a new multiple myeloma drug will brighten the outlook for people with resistant forms of the disease.
Medical oncologist Ghassan Abou-Alfa led the clinical trial that resulted in the FDA’s approval of a new combination therapy for hepatocellular cancer.
FDA Approves New Immunotherapy Combination To Treat Advanced Liver Cancer

Patients with inoperable advanced liver cancer have a new option for treatment to extend their lives.
Memorial Sloan Kettering breast cancer patient Linda Dow
When Breast Cancer Surgery Isn’t an Option, Cryoablation Can Offer Hope

Learn about cryoablation for breast cancer at Memorial Sloan Kettering Cancer Center.
A slide being reviewed under a microscope
MSK Research Highlights, October 13, 2022

New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute suggests a therapeutic strategy to overcome resistance to PRMT5 inhibition in lymphoma; finds safety and clinical benefit using an engineered adenovirus in combination with immunotherapy against PD-1-resistant melanoma; and uncovers a new type of immune cell that plays a key role in establishing a healthy gut microbiome.